同种LAK细胞、5－FU等抗癌剂腹腔注入治疗原发性肝癌腹水的临床观察

本文采用同种ＬＡＫ细胞联合ＩＬ－２腹腔注入（ＩＰ），５－ＦＵ联合ＭＭＣ、ＣＢＤＣＡ腹腔注入，同种ＬＡＫ细胞联合ＩＬ－２静脉输入以及放腹水、利尿、补充白蛋白等方法，分别治疗晚期ＰＨＣ腹水患者共４０例，结果表明，同种ＬＡＫ细胞联合ＩＬ－２经ＩＰ（１０例），５－ＦＵ联合ＭＭＣ、ＣＢＤＣＡ经ＩＰ（１０例），均使４例（４０％）腹水减少或消失、症状明显改善；同种ＬＡＫ细胞联合ＩＬ－２全身治疗（１０例），以及放腹水、利尿、补充白蛋白等一般治疗（１０例），均仅使１例（１０％）腹水减少，疗效欠佳；结果提示，腹腔内ＬＡＫ联合ＩＬ－２治疗及腹腔内５－ＦＵ联合ＭＭＣ、ＣＢＤＣＡ化疗，是值得推荐的治疗晚期肝癌腹水的手段之一。

Clinical Observation of Treatment by IntraperitonealAdministration of LAK Cells, 5-FU in Patients with Ascites Due to Primary Hepatocellular Carcinoma

A comparative study was carried out in 40 patients with ascites due to advanced PHC treated by intraperitoneal (IP) administration of allogenic LAK cells combined with IL-2(10 patients), 5-FU combined with MMC, CBDCA (10 patients),intravenous injection of LAK cells combined with IL2 ( 10 patients) and diuretic therapy and intraperitoneal drainage therapy (10 patients). Of these 40 patients, 4 treated by IP administration of LAK combined with IL-2 and 4 treated by IP administration of 5-FU combined with MMC,CBDCA could reduced the amount of ascites, improved clinical symptoms, 1 treated by intravenous injection of LAK combined with IL-2 and 1 treated by diuretic therapy, intraperitoneal drainage therapy could reduced the amount of ascites. The results indicated that IP administration of LAK combined with IL-2 or of 5-FU combined with MMC, CBDCA in the patients with ascites due to advanced PHC is a recommendable treatment.